News › Benzinga

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Benzinga • Jan 7, 2026 8:55am (New York) •By Prnewswire

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 million in outstanding debt, convertible notes, warrants, and royalty interests with Scilex.

← Back to news Read Original Article

Insights

ORMP positive

Company received substantial $18 million payment closing obligations, achieved $118 million returns on $99.5 million investment (19% gain), approved shareholder dividend of $0.25/share, and retains significant remaining assets ($39 million) including convertible notes and royalty interests, demonstrating strong financial performance and shareholder returns.

Keywords

#dividend payment #investment returns #Scilex Holdings #oral drug delivery #pharmaceutical company #convertible notes #warrant position #royalty interest

Tickers

ORMP SCLX SCLXW

← Prev: Private Hiring Rebounds In December, But Labor Market Still Limping

Next: VIVUS Introduces Lower Pricing on QSYMIA® at Costco Locations Across Hawaii →